US Patent

US11234972 — Methods of treating fabry disease in patients having the G9331A mutation in the GLA gene

Method of Use · Assigned to Amicus Therapeutics Inc · Expires 2037-03-15 · 11y remaining

Vulnerability score 53/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects methods of treating Fabry disease in patients with a specific genetic mutation using a pharmacological chaperone.

USPTO Abstract

Provided are methods of treating a patient diagnosed with Fabry disease and methods of enhancing α-galactosidase A in a patient diagnosed with or suspected of having Fabry disease. Certain methods comprise administering to a patient a therapeutically effective dose of a pharmacological chaperone for α-galactosidase A, wherein the patient has a splice site mutation in intron 4 of the nucleic acid sequence encoding α-galactosidase A. Also described are uses of pharmacological chaperones for the treatment of Fabry disease and compositions for use in the treatment of Fabry disease.

Drugs covered by this patent

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

CodeDescriptionDrug
U-2371 — migalastat-hydrochloride

Patent Metadata

Patent number
US11234972
Jurisdiction
US
Classification
Method of Use
Expires
2037-03-15
Drug substance claim
No
Drug product claim
No
Assignee
Amicus Therapeutics Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.